Curated News
By: NewsRamp Editorial Staff
June 15, 2026
Telomir-Zn Restores Insulin Sensitivity in Diabetes Study
TLDR
- Telomir Pharmaceuticals' Telomir-Zn restores insulin sensitivity, offering a competitive edge in diabetes treatment.
- Telomir-Zn modulates intracellular metal homeostasis, reducing blood glucose and insulin levels in zebrafish diabetes model.
- Telomir-Zn could improve millions of lives by reversing insulin resistance and enhancing glucose control in diabetes.
- Telomir-Zn targets both metabolic disease and cancer, potentially revolutionizing treatment for two major health challenges.
Impact - Why it Matters
This news matters because it suggests Telomir-Zn could be a novel therapeutic approach for Type 2 diabetes, a condition affecting hundreds of millions worldwide. The drug's dual potential in both metabolic disease and cancer—via a common mechanism of metal homeostasis—could lead to broad clinical applications, offering hope for patients with limited treatment options. Additionally, the ongoing Phase 1/2 trial in triple-negative breast cancer underscores the drug's versatility, potentially addressing unmet needs in oncology as well.
Summary
Telomir Pharmaceuticals (NASDAQ: TELO) has announced the peer-reviewed publication of preclinical data in Biomedicine & Pharmacotherapy, demonstrating that its lead candidate, Telomir-Zn, restored insulin sensitivity and improved glucose homeostasis in a diet-induced zebrafish model of Type 2 diabetes. The study showed dose-dependent reductions in fasting blood glucose and insulin levels, improved glucose tolerance, and significantly lowered HOMA-IR scores—a standard measure of insulin resistance. These findings add to a growing body of evidence supporting Telomir-Zn’s mechanism of action through modulation of intracellular metal homeostasis, a pathway implicated in both metabolic disease and cancer. The company noted that the results complement its recently FDA-cleared Phase 1/2 clinical program evaluating Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer, highlighting the drug’s potential across multiple therapeutic areas.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental epigenetic and metabolic mechanisms involved in cancer, aging, and degenerative disease. Its lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. The company’s news and updates are available in its newsroom at https://ibn.fm/TELO.
This press release was disseminated by BioMedWire, a specialized communications platform focused on the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, enhanced press release distribution, social media distribution, and tailored corporate communications solutions. For more information, visit BioMedWire.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Telomir-Zn Restores Insulin Sensitivity in Diabetes Study
